Ix Biopharma Ltd. announced the appointment of Lam Li Fong as general manager, effective September 25, 2015. He is responsible for the overall management and operations of Syrinx Pharmaceuticals which operates the company's manufacturing facility. Previously he worked as chief executive officer of Oversee Arrow Laboratories operations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 SGD | -2.50% | 0.00% | -13.33% |
03-12 | Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer | MT |
03-12 | IX Biopharma Introduces New Sublingual Wafer | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.33% | 22.2M | |
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- 42C Stock
- News iX Biopharma Ltd.
- Ix Biopharma Ltd. Announces Appointment of Lam Li Fong as General Manager